CAN/CGSB 1.186-M89 PDF

CAN/CGSB 1.186-M89 PDF

Name:
CAN/CGSB 1.186-M89 PDF

Published Date:
02/01/1996

Status:
[ Withdrawn ]

Description:

High Performance Glazed Coating System, Interior

Publisher:
Canadian General Standards Board

Document status:
Active

Format:
Electronic (PDF)

Delivery time:
10 minutes

Delivery time (for Czech version):
200 business days

SKU:
can-cgsb-1-186-m89_1089134

Choose Document Language:
0
Need Help?


This standard applies to an architectural coating system consisting of base coats and/or glaze coats and may include a filler if conditions warrant it. The system is intended for use on interior walls and ceilings to provide a high performance glaze finish resistant to moisture, staining and fire.

For more detailed information on intended uses, see par. 7.2.

This standard may require the use of materials and/or equipment that could be hazardous. This document does not purport to address all the safety aspects associated with its use. Anyone using this standard has the responsibility to consult the appropriate authorities and to establish appropriate health and safety practices in conjunction with any existing applicable requirements prior to its use.

Time-dated standard

File Size : 1 file , 14 MB
Note : This product is unavailable in Russia, Belarus
Published : 02/01/1996

History


Related products

CAN/CGSB 4.2 NO. 17-M90
Published Date: 02/01/1990
Textile Test Methods - Cuprammonium Fluidity of Textile Cellulose
CAN/CGSB 2.19-96
Published Date: 10/01/1996
Detergent pour lavage de la vaisselle a la main
CAN/CGSB 19.6-M87
Published Date: 02/01/1987
Mastic de calfeutrage, a base d'huile
CAN/CGSB 3.512-2013
Published Date: 09/01/2014
Automotive Ethanol Fuel (E50-E85), Amended September 2014

Best-Selling Products

Alzheimer's Disease Report
Published Date: 12/01/2018
2398.50 €
Cystic Fibrosis Disease Report
Published Date: 04/01/2019
2398.50 €
Multiple Sclerosis Disease Report
Published Date: 12/01/2018
2398.50 €
Non-Alcoholic Steatohepatitis Disease Report
Published Date: 12/01/2018
2398.50 €
Non-Hodgkin's Lymphoma Disease Report
Published Date: 12/01/2018
2398.50 €